← Back to Search

Antisense Oligonucleotide

Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia (SHASTA-2 Trial)

Phase 2
Waitlist Available
Research Sponsored by Arrowhead Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years

Summary

This trial is testing a new treatment called ARO-APOC3 for people with very high levels of blood fats. The treatment involves two injections and works by reducing a protein that helps control these fats. The goal is to see if it is safe and effective.

Eligible Conditions
  • Severe Hypertriglyceridemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: ARO-APOC3 50 mg, Day 1 and Week 12Experimental Treatment1 Intervention
2 doses of ARO-APOC3 by sc injection
Group II: ARO-APOC3 25 mg, Day 1 and Week 12Experimental Treatment1 Intervention
2 doses of ARO-APOC3 by sc injection
Group III: ARO-APOC3 10 mg, Day 1 and Week 12Experimental Treatment1 Intervention
2 doses of ARO-APOC3 by subcutaneous (sc) injection
Group IV: Placebo, Day 1 and Week 12Placebo Group1 Intervention
calculated volume to match active treatment by sc injection
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ARO-APOC3
2019
Completed Phase 2
~700

Find a Location

Who is running the clinical trial?

Arrowhead PharmaceuticalsLead Sponsor
41 Previous Clinical Trials
4,816 Total Patients Enrolled
5 Trials studying Hypertriglyceridemia
2,238 Patients Enrolled for Hypertriglyceridemia

Media Library

ARO-APOC3 (Antisense Oligonucleotide) Clinical Trial Eligibility Overview. Trial Name: NCT04720534 — Phase 2
Hypertriglyceridemia Research Study Groups: ARO-APOC3 25 mg, Day 1 and Week 12, ARO-APOC3 10 mg, Day 1 and Week 12, ARO-APOC3 50 mg, Day 1 and Week 12, Placebo, Day 1 and Week 12
Hypertriglyceridemia Clinical Trial 2023: ARO-APOC3 Highlights & Side Effects. Trial Name: NCT04720534 — Phase 2
ARO-APOC3 (Antisense Oligonucleotide) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04720534 — Phase 2
~51 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top